Enliven治疗学报告称,在治疗抗药性慢性流质白血病方面,ELVN-001第1b阶段的成果大有希望,38%取得了重大的分子反应。 Enliven Therapeutics reports promising Phase 1b results for ELVN-001 in treating resistant chronic myeloid leukemia, with 38% achieving major molecular response.

Enliven治疗学报告说,其实验药物ELVN-001在治疗耐抗或不耐抗以前疗法的慢性流血性白血病病人方面,取得了第1b阶段的积极成果。 Enliven Therapeutics reported positive Phase 1b results for its experimental drug ELVN-001 in treating chronic myeloid leukemia patients resistant or intolerant to prior therapies. 60名病人中,80毫克剂量的38%在第24周达到主要分子反应(MMR),16%达到深分子反应(DMR),低剂量组和高剂量组的比例较高。 Among 60 patients, 38% on the 80 mg dose achieved major molecular response (MMR) and 16% deep molecular response (DMR) by week 24, with higher rates in combined lower and higher dose groups. 该药物在剂量间表现出一贯的功效和安全性,没有新的安全关切。 The drug showed consistent efficacy and safety across doses, with no new safety concerns. 该公司计划提交更多第1阶段2026年中期的数据,为第3阶段选择剂量,并于当年晚些时候启动Enable-2试验。 The company plans to present more Phase 1 data mid-2026, select a dose for Phase 3, and launch the ENABLE-2 trial later that year.